Cargando…
Review of frovatriptan in the treatment of migraine
Triptans are recommended for the acute treatment of moderate to severe migraine or failure to respond to other acute migraine treatments. Seven triptans are available providing a wide range of choices. These triptans are more similar than dissimilar but patients do note differences in effectiveness...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515913/ https://www.ncbi.nlm.nih.gov/pubmed/18728819 |
_version_ | 1782158453882486784 |
---|---|
author | Kelman, Leslie |
author_facet | Kelman, Leslie |
author_sort | Kelman, Leslie |
collection | PubMed |
description | Triptans are recommended for the acute treatment of moderate to severe migraine or failure to respond to other acute migraine treatments. Seven triptans are available providing a wide range of choices. These triptans are more similar than dissimilar but patients do note differences in effectiveness and in tolerance. Also migraine situations may differ from attack to attack, providing the opportunity to exploit the uniqueness of a particular triptan. Frovatriptan has a uniquely long-half life, five times that of other triptans. This provides the opportunity to use frovatriptan in mini-prophylaxis such as in menstrual-related migraine and other situations, as well as use in long-lasting or recurrent migraine. |
format | Text |
id | pubmed-2515913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-25159132008-08-26 Review of frovatriptan in the treatment of migraine Kelman, Leslie Neuropsychiatr Dis Treat Expert Opinion Triptans are recommended for the acute treatment of moderate to severe migraine or failure to respond to other acute migraine treatments. Seven triptans are available providing a wide range of choices. These triptans are more similar than dissimilar but patients do note differences in effectiveness and in tolerance. Also migraine situations may differ from attack to attack, providing the opportunity to exploit the uniqueness of a particular triptan. Frovatriptan has a uniquely long-half life, five times that of other triptans. This provides the opportunity to use frovatriptan in mini-prophylaxis such as in menstrual-related migraine and other situations, as well as use in long-lasting or recurrent migraine. Dove Medical Press 2008-02 2008-02 /pmc/articles/PMC2515913/ /pubmed/18728819 Text en © 2008 Dove Medical Press Limited. All rights reserved |
spellingShingle | Expert Opinion Kelman, Leslie Review of frovatriptan in the treatment of migraine |
title | Review of frovatriptan in the treatment of migraine |
title_full | Review of frovatriptan in the treatment of migraine |
title_fullStr | Review of frovatriptan in the treatment of migraine |
title_full_unstemmed | Review of frovatriptan in the treatment of migraine |
title_short | Review of frovatriptan in the treatment of migraine |
title_sort | review of frovatriptan in the treatment of migraine |
topic | Expert Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515913/ https://www.ncbi.nlm.nih.gov/pubmed/18728819 |
work_keys_str_mv | AT kelmanleslie reviewoffrovatriptaninthetreatmentofmigraine |